Testosterone therapy in older men: benefits, risks and safe use

Testosterone levels often decline gradually with age, but ageing alone does not prove that treatment is needed. A diagnosis of testosterone deficiency usually requires consistent symptoms alongside repeatedly low morning testosterone results. Sexual difficulties, reduced energy, loss of muscle strength, depressed mood and fewer spontaneous erections can have many other causes, including diabetes, obesity, sleep apnoea, medication effects and cardiovascular disease.

Testosterone replacement therapy (TRT) may improve sexual desire, erectile function in some men, lean body mass and bone density when genuine hypogonadism is present. The likely benefit depends on the reason for the low result, the severity of symptoms and the individual’s broader health. It is less likely to provide a dramatic “anti-ageing” effect in a man whose hormone levels are within the expected range.

Older Australians commonly begin this discussion with a general practitioner, who can arrange blood tests and review medicines before referring to an endocrinologist or urologist. Access varies between metropolitan areas such as Sydney, Melbourne and Brisbane and regional communities, where specialist appointments and pathology services may require additional travel.

Treatment also sits within Australia’s regulated medicines system. Testosterone gels, injections and other formulations require a prescription, while Pharmaceutical Benefits Scheme access depends on approved indications and eligibility. Some men pay privately for treatment, making regular monitoring important for both safety and value.

When low testosterone warrants assessment

Symptoms should be interpreted as a pattern rather than a single complaint. Reduced libido and fewer morning erections are relatively suggestive, while tiredness, irritability and poor concentration are less specific. Loss of body hair, smaller testes, infertility, hot flushes and reduced bone density can point towards androgen deficiency, particularly when they occur with low laboratory results.

Testing is usually performed in the morning because testosterone follows a daily rhythm. A low result should generally be repeated, using a reliable assay, before treatment begins. Clinicians may also measure sex hormone-binding globulin, free testosterone, luteinising hormone and follicle-stimulating hormone to distinguish testicular failure from a pituitary or hypothalamic cause.

A careful history matters. Opioid pain medicines, corticosteroids, heavy alcohol use, severe illness and substantial weight gain can suppress testosterone. Obstructive sleep apnoea, which is often underdiagnosed in older men, can affect energy and sexual function and may need treatment before hormone therapy is considered. A broader clinical reference can help explain how endocrine symptoms overlap with other conditions (medical guidance).

Potential benefits for sexual and physical health

The clearest potential benefit of TRT is improvement in sexual desire when low testosterone is confirmed. Some men experience better erectile function, although testosterone is not a substitute for proven erectile-dysfunction treatments such as phosphodiesterase type 5 inhibitors. Erectile problems may reflect vascular disease, so they deserve assessment rather than being attributed automatically to hormones.

Clinical studies suggest that replacement can modestly improve lean muscle mass and reduce fat mass. Gains in strength are less predictable and are greatest when therapy is combined with resistance exercise and adequate protein. Men should be wary of promises involving rapid muscle growth, enhanced athletic performance or a guaranteed restoration of youth.

Bone health is another relevant consideration. Testosterone can increase bone mineral density, particularly in men with marked deficiency, but fracture prevention remains less certain. Calcium intake, vitamin D status, weight-bearing activity and assessment for osteoporosis may be equally important. A bone-density scan may be appropriate when there is a history of fractures, prolonged steroid use or other risk factors.

Mood and cognition require realistic expectations. Some men report improved motivation or wellbeing after correcting genuine deficiency, but TRT is not established treatment for depression, dementia or ordinary age-related forgetfulness. Persistent mood symptoms should be assessed independently, including for sleep disorders and social isolation.

Cardiovascular, prostate and blood-related risks

Testosterone stimulates red blood cell production. If the haematocrit rises too far, blood may become more viscous, increasing concern about clotting and vascular events. A full blood count is therefore checked before treatment and periodically afterwards. A persistently high haematocrit may require dose reduction, temporary cessation or investigation for sleep apnoea and other causes.

Cardiovascular safety has been closely studied and remains a matter for individual risk assessment. Current evidence does not support using TRT casually to prevent heart disease. Men with a recent heart attack or stroke, uncontrolled heart failure or significant untreated sleep apnoea may need to defer treatment. Blood pressure, cholesterol, diabetes, smoking and weight should be addressed as part of the same review.

Testosterone can increase prostate-specific antigen (PSA) and prostate volume, although it has not been proven to initiate prostate cancer. A baseline prostate assessment is generally needed, followed by monitoring according to age, symptoms and risk. New urinary difficulty, blood in the urine or a rising PSA requires prompt medical review rather than automatic continuation.

Lower urinary tract symptoms are common in older Australian men and may be caused by benign prostate enlargement, infection, stones or neurological dysfunction. Evidence does not show that carefully monitored TRT inevitably worsens urinary symptoms, but severe untreated obstruction calls for caution. Urological research, including work on bladder function and voiding disorders, is available through Urological Science.

Choosing a formulation and monitoring treatment

Gels are applied daily to the skin and can provide relatively steady levels, but they require consistent use and precautions to prevent transfer to children or partners through skin contact. Hands should be washed after application, and the area should remain covered once dry. Accidental exposure can be particularly concerning for children.

Long-acting injections reduce daily treatment demands but may produce fluctuations in symptoms and hormone levels. Shorter-acting injections offer more flexibility when adjusting therapy, though they involve more frequent appointments or self-administration. Oral, implantable and compounded products may have specific limitations; products obtained from unregulated online suppliers can carry serious quality and dosing risks.

Monitoring commonly includes testosterone levels, symptoms, full blood count, PSA where appropriate, blood pressure and adverse effects. The timing of a blood test depends on the formulation: testing at the wrong point in an injection cycle or too soon after applying a gel can produce misleading results. The prescribing clinician should specify when and how the sample is collected.

Treatment should have a defined review point. If symptoms do not improve after testosterone has reached an appropriate range, continuing indefinitely is difficult to justify. Dose escalation to chase a higher number can increase harm without adding meaningful benefit. A urologist, endocrinologist or experienced GP can review the response and decide whether continuation remains appropriate.

Situations requiring extra caution

Men with prostate or breast cancer should not start testosterone without specialist assessment. A suspicious prostate examination, unexplained PSA elevation, severe urinary obstruction or a high haematocrit also requires investigation first. Fertility is another important issue: external testosterone suppresses sperm production and is unsuitable for men trying to conceive.

TRT may worsen acne, oily skin, breast tenderness, fluid retention or male-pattern hair loss. It can aggravate untreated sleep apnoea and may affect mood, particularly when doses fluctuate or exceed physiological replacement. Men should report chest pain, severe breathlessness, one-sided leg swelling, sudden neurological symptoms or marked urinary changes urgently.

Interactions and coexisting illness influence the decision. Anticoagulant use, chronic kidney or liver disease, diabetes and sleep medicines should be disclosed. A complete medication list should include supplements and products bought from gyms or online retailers, since some may contain undisclosed anabolic steroids.

Older men often have several plausible explanations for low energy or sexual difficulty. Managing obesity, walking regularly, undertaking resistance training, limiting alcohol, improving sleep and treating diabetes can improve testosterone physiology and quality of life without exposing someone to hormone-related adverse effects. These measures can also make any prescribed treatment more effective.

A urology-focused evidence source can place hormone decisions alongside prostate, bladder and kidney care; the journal’s research illustrates why urinary symptoms may involve complex biological factors rather than one simple cause. Similarly, specialist assessment of difficult voiding may involve investigations such as urodynamics, as described in this discussion of urodynamic testing.

Testosterone replacement therapy in older men is best viewed as a monitored treatment for confirmed deficiency, not a general response to ageing. Men considering it should arrange a structured consultation with an Australian GP, review the evidence and alternatives, complete appropriate baseline testing, and attend follow-up appointments so benefits and risks can be reassessed over time.